Sjogren’s Syndrome is a condition that causes immune cell infiltration into the salivary and lacrimal glands, leading to dry mouth and dry eyes. No cure exists and treatments only somewhat alleviate symptoms. Two novel methods for treating, and potentially curing, Sjogren’s are under development. The first uses Resolvin D1 to improve salivary gland epithelial integrity in cytokine-damaged cells. Through localized delivery or intravenous administration for systemic delivery of a proprietary combination into glands to treat dry mouth and dry eye. The second uses a fibrin-based hydrogel used to regenerate salivary glands. The hydrogel is combined with functional groups, which are chemically conjugated to fluorescent FH to form new salivary tissue and eliminate dry mouth.

• Reduces or eliminates pain, difficulty swallowing, speech problems and other symptoms of dry mouth in Sjogren’s patients.
• Promotes tissue regeneration for salivary glands.
• Lowers manufacturing cost.
• Initial studies indicate good biocompatibility.
• Provides a potential cure for Sjogren’s Syndrome.


**INVENTOR PROFILE**
Olga Baker, D.D.S., Ph.D., Associate Professor - Dentistry

DATE UPDATED: 12/14/2017